Page 16 - 020222_Badan POM Terbitkan Persetujuan Penggunaan Darurat Vaksin Sinopharm sebagai Dosis Booster

Judul : BPOM Approves Sinopharm as Booster Vaccine Al

Nama Media : tempo.co

Tanggal : 2 Februari 2022
Halaman/URL : https://en.tempo.co/read/1556534/bpom-approves-sinopharm-
as-booster-vaccine-alternative

Tipe Media : Online

The Indonesian Food and Drugs
Monitoring Agency (BPOM) has
issued an emergency use
authorization (EUA) for the
Sinopharm vaccine as the country’s
sixth booster alternative.

Citing Antaranews, BPOM head
Penny Lukito in a written statement
on February 2 said “the agency has
evaluated the beneficial aspect and
safety aspect based on the Covid-19 vaccine standard evaluation for Sinopharm as a
booster dose for people aged 18 and above.”

Sinopharm is a vaccine produced by the Beijing Bio-Institute of Biological Products
and has been registered in Indonesia by Kimia Farma for homolog booster use on
people aged 18 years and above who have received complete vaccine dose six
months prior.

Based on the safety aspect, Penny said, the use of Sinopharm as a booster jab is
generally tolerable and has lower side effects compared to effects caused in the
primary vaccinations.

Based on the study of the immunogenicity aspect, tests show an increase in the
humoral immune response for the measurement parameters of neutralizing antibody
and anti-IgG by 8.4 times and 8 times, respectively, compared to before the booster
was administered.

The BPOM Head acknowledged and lauded the National Committee for Assessing the
Covid-19 Vaccine expert team that helped the release of Sinopharm as a booster
alternative.